Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Newron Pharmaceuticals SpA
SIX:NWRN
Newron Pharmaceuticals SpA
SIX:NWRN
Price:
8.07
CHF
-1.34%
Market Closed
Market Cap:
CHf167.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Newron Pharmaceuticals SpA
SIX:NWRN
|
IT |
|
E
|
Entegris Inc
F:ENQ
|
US |
|
Anika Therapeutics Inc
NASDAQ:ANIK
|
US |
|
H
|
Henkel AG & Co KGaA
DUS:HEN
|
DE |
|
C
|
Celanese Corp
LSE:0HUR
|
US |
|
Fidus Investment Corp
NASDAQ:FDUS
|
US |
|
C
|
Caster Co Ltd
TSE:9331
|
JP |
Wall St Price Targets
NWRN Price Forecast
Based on 8 analysts
Based on 8 analysts
+342% Upside
from
CHf8.07
today
Newron Pharmaceuticals SpA (NWRN)’s 12-month stock price forecast through October 2027 has a consensus target of CHf35.7, implying 342% upside. The forecast is based on price targets from 8 Wall Street analysts.
NWRN Analyst Rating
No ratings yet
No ratings yet
Newron Pharmaceuticals SpA Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NWRN's stock price target?
Price Target
35.7
CHF
35.7
CHF
According to Wall Street analysts, the average 1-year price target for NWRN is 35.7 CHF with a low forecast of 21.11 CHF and a high forecast of 76.65 CHF.
What is the Revenue forecast for Newron Pharmaceuticals SpA?
Projected CAGR
40%
40%
Over the last 14 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 8 years is 40%.
What is the Gross Profit forecast for Newron Pharmaceuticals SpA?
Projected CAGR
67%
67%
The compound annual growth rate for Gross Profit over the next 2 years is 67%.